Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03838263
Title Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer (IMMUNEBOOST)
Acronym IMMUNEBOOST
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors UNICANCER
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST